Welcome to our dedicated page for BioAge Labs SEC filings (Ticker: BIOA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing 200+ pages of biotechnology disclosures is hard, especially when BioAge Labs Inc. (BIOA) updates investors on drug trials, licensing milestones, and cash runway in every report. If you have ever opened a BioAge Labs annual report 10-K and wondered where the pipeline timelines actually hide, you are not alone.
Stock Titan solves this challenge by pairing each document with AI-powered summaries that translate technical language into clear takeaways. Open the latest BioAge Labs quarterly earnings report 10-Q filing and our platform highlights trial spending trends, while our real-time alerts flag BioAge Labs Form 4 insider transactions the moment executives trade shares.
Every SEC form is covered and searchable:
- 10-K: BioAge Labs annual report 10-K simplified—cash runway analyses, clinical risk factors, IP strategy.
- 10-Q: Side-by-side revenue and R&D comparisons plus AI comments for quick BioAge Labs earnings report filing analysis.
- 8-K: BioAge Labs 8-K material events explained—from Phase 1 topline data to financing agreements.
- DEF 14A: BioAge Labs proxy statement executive compensation decoded, including option grants tied to trial milestones.
- Form 4: BioAge Labs insider trading Form 4 transactions streamed in seconds, giving you BioAge Labs Form 4 insider transactions real-time visibility.
Need context fast? Ask natural questions like “understanding BioAge Labs SEC documents with AI� and jump directly to the section that matters—whether it is apelin receptor data or dilution clauses. Professionals use these insights to monitor executive stock transactions, compare quarter-over-quarter R&D spend, and assess how upcoming readouts may impact valuation. Complex filings made clear, updated the moment they hit EDGAR.
ADAR1 Capital Management, LLC and Daniel Schneeberger report shared beneficial ownership of 1,937,123 shares of BioAge Labs common stock, representing 5.4% of the 35,850,037 shares outstanding. The reported position reflects holdings attributable to ADAR1 Partners, LP (1,662,162 shares) and Spearhead Insurance Solutions IDF, LLC (274,961 shares), with voting and dispositive power held jointly by the reporting persons through their advisory and managerial roles.
The filing is submitted on Schedule 13G as a passive disclosure and includes a certification that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
BioAge Labs, Inc. is reported to have meaningful institutional ownership from Cormorant Asset Management, LP and Bihua Chen, who together beneficially own 2,140,605 shares of common stock, representing 5.97% of the company's outstanding common shares based on 35,850,037 shares outstanding as of August 1, 2025.
The filing shows shared voting and shared dispositive power for all reported shares (no sole voting or dispositive power). It is submitted on Schedule 13G/A and includes certifications that the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.
BioAge Labs insider grant: Director Pande Vijay Satyanand was granted 22,000 stock options on 08/07/2025 allowing purchase of common stock at an exercise price of $4.32. The filing reports the award as a derivative security acquired and shows 22,000 derivative securities beneficially owned following the transaction, held in a direct form of ownership. The option award's vesting is explicit: it vests in full on the earlier of the next annual meeting or the one-year anniversary of the grant date, subject to continued service. The award appears to expire on 08/06/2035. The form is signed by an attorney-in-fact on 08/11/2025.
FAQ
What is the current stock price of BioAge Labs (BIOA)?
What is the market cap of BioAge Labs (BIOA)?
